99mTc-labeled vasoactive intestinal peptide receptor agonist: Functional studies

Journal of Nuclear Medicine

Volumn 40, Issue 2, 1999, Pages 352-360

  Pallela, Venkat R ^a   Thakur, Mathew L ^a   Chakder, Sushanta ^a   Rattan, Satish ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

99mTc; Colorectal tumors; Hybrid peptide technique; Imaging; Vasoactive intestinal peptide

Indexed keywords

TECHNETIUM 99M; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; DIAGNOSTIC AGENT; OLIGOPEPTIDE; RADIOACTIVE IODINE; TECHNETIUM; TP 3654;

ANIMAL EXPERIMENT; ARTICLE; CANCER SCINTISCANNING; COLORECTAL CANCER; DISEASE MARKER; DRUG CLEARANCE; ISOTOPE LABELING; NONHUMAN; OPOSSUM; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN DETERMINATION; TISSUE DISTRIBUTION; ANIMAL; BINDING COMPETITION; CANCER TRANSPLANTATION; CELL CULTURE; COLORECTAL TUMOR; DRUG EFFECT; DRUG POTENTIATION; HUMAN; IN VITRO STUDY; METABOLISM; MOUSE; MUSCLE CONTRACTION; NUDE MOUSE; RAT; SCINTISCANNING; SMOOTH MUSCLE; SPRAGUE DAWLEY RAT; SYNTHESIS; XENOGRAFT;

ANIMALS; BINDING, COMPETITIVE; COLORECTAL NEOPLASMS; HUMANS; IODINE RADIOISOTOPES; MICE; MICE, NUDE; MUSCLE CONTRACTION; MUSCLE, SMOOTH; NEOPLASM TRANSPLANTATION; OLIGOPEPTIDES; OPOSSUMS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; TECHNETIUM; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; VASOACTIVE INTESTINAL PEPTIDE;

EID: 0032588617     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Hokfelt T. Neuropepticides in perspective: the last ten years. Neuron. 1991;7:867-879.
2. Sivolapenko GB, Douli V, Pectasides D, et al. Breast cancer imaging with radiolabeled peptide from complementary determining region of anti-tumor antibody. Lancet. 1995;346:1612-1616.
3. 3) octreotide. The Rotterdam experience with more than 1000 patients. Eur J Nucl Med. 1993;20:716-731.
4. Reubi JC. In vitro identification of vasoactive intestinal peptide receptors in human tumors: implications for tumor imaging. J Nucl Med. 1995;36:1846-1853.
5. Zia F. Breast cancer growth is inhibited by vasoactive intestinal peptide (VIP) hybrid, a synthetic VIP receptor antagonist. Cancer Res. 1996;56:3486-3489.
6. Harmar T, Lutz E. Multiple receptors for PACAP and VIP. Trends Pharmacol Sci. 1994;15:97-98.
7. Zoghbi SS, Thakur ML, Gottschalk A, et al. Selective cell labeling: a potential radioactive agent for labeling human neutrophils [abstract]. J Nucl Med. 1981;22:32P.
8. Van der Laken CJ, Boerman OC, Oyen WJG, et al. Technetium-99m labeled chemotactic peptides in acute infection and sterile inflammation. J Nucl Med. 1997;38:1310-1315.
9. Babich JW, Tompkins RG, Graham W, Barrow SA, Fischman AJ. Localization of radiolabeled chemotactic peptide at focal sites of Escherichia coli infection in rabbits: evidence for a receptor-specific mechanism. J Nucl Med. 1997;38:1316-1322.
10. Sostman HD, Thakur ML, Zoghbi SS, et al. Influence of heparin on in vivo distribution of In-111 labeled platelets. Invest Radiol. 1985;20:198-202.
11. Pearson DA, Lister-James J, McBride WJ, et al. Thrombus imaging using Tc-99m labeled high potency GPIIb/IIIa receptor antagonist: chemistry and initial biological studies. J Med Chem. 1990;39:1372-1382.
12. Line BR, Cran P, Lazewatsky J, et al. Phase I trial of DMP444, a new thrombus imaging agent [abstract]. J Nucl Med. 1996;37:117P.
13. 1H-NMR and computer modeling conformational analysis. J Biol Chem. 1994;269:12583-12588.
14. Thakur ML, Kolan HR, Rifat S, et al. Vapreotide labeled with Tc-99m for imaging tumors: preparation and preliminary evaluation. Int J Oncol. 1996;9:445-451.
15. Kolan H, Li J, Thakur ML. Sandostalin® labeled with Tc-99m: in vitro stability, in vivo validity and comparison with In-111-DTPA-octreotide. Peptide Res. 1996;9: 144-150.
16. Thakur ML, Kolan HR, Rifat S, et al. Vapreotide labeled with Tc-99m for imaging tumor: preparation and preliminary evaluation. Int J Oncol. 1996;9:445-451.
17. Thakur ML, Kolan H, Li J, et al. Radiolabeled somatostatin analogs in prostate cancer. Nucl Med Biol. 1997;24:105-113.
18. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from the small intestine. Science. 1970;69:1217-1218.
19. Virgolini I, Yang Q, Li S, et al. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors. Cancer Res. 1994;54:690-700.
20. Blum AM, Mathew R, Cook GA, Metwali A, Felman R, Weinstock JV. Murine mucosal T cells have VIP receptors functionally distinct from those on intestinal epithelial cells. J Neuroimmunol. 1992;39:101-108.
21. Moody TW. Peptides and growth factors in non-small cell lung cancer. Peptides. 1995;17:545-555.
22. Paul S, Said SI. Characterization of receptors for vasoactive intestinal peptide solubilized from the lung. J Biol Chem. 1987;262:158-162.
23. Couvineau A, Luburthe M. The human vasoactive intestinal peptide receptor: molecule identification by covalent cross-linking in colonic epithelium. J Clin Endocrinol Metab. 1985;61:50-55.
24. Sreedharan SP, Robichon A, Peterson KE, Goetzl EJ. Cloning and expression of the human vasoactive intestinal peptide receptor. Proc Natl Acad Sci USA. 1991;88:4986-1990.
25. el Battari A, Martin JM, Luis J, et al. Solubilization of the active vasoactive intestinal peptide receptor from human colonic adenocarcinoma cells. J Biol Chem. 1988;263:17685-17689.
26. Virgolini I, Raderer M, Kurtaran M, et al. Vasoactive intestinal peptide receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors. N Engl J Med. 1994;331:1116-1121.
27. Svoboda M, De Neef P, Tastenoy M, Christophe J. Molecular characterization and evidence for internalization of vasoactive intestinal peptide (VIP) receptors in the tumoral rat-pancreatic acinar cell line AR 4-2 J. Eur J Biochem. 1988;176:707-713.
28. Reubi JC. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging. J Nucl Med. 1995;36:1825-1835.
29. Reubi JC, Waser B, Laissue JA, et al. Somatostatin and vasoactive intestinal peptide receptors in human tumors: in vitro identification. Cancer Res. 1996;56: 1922-1931.
30. Kolan HR, Pallela VR, Thakur ML. Technetium-99m labeled vasoactive intestinal peptide (VIP): preparation and preliminary evaluation. J Labelled Cpd Radiopharm. 1997;40:455-157.
31. Chakder S, Rattan S. The entire vasoactive intestinal polypeptide molecule is required for the activation of the vasoactive intestinal polypeptide receptor: functional and binding studies. J Pharm Exp Therapeut. 1993;266:392-399.
32. Vanbilloen HP, Bormans GM, De Roo MK, Verbruggen AM. Complexes of technetium-99m with tetrapeptides, a new class of Tc-99m labeled agents. Nucl Med Biol. 1995;33:325-338.
33. Pallela VR, Thakur ML, Ramanna R, Senadhi V, et al. Synthesis and evaluation of Tc-99m labeled VIP analogs as potential tumor imaging agents [abstract]. J Nucl Med. 1998;39:226P.
34. Moummi C, Rattan S. Effect of methylene blue and N-ethylmeleimide on internal anal sphincter relaxation. Am J Physiol. 1988;255:G571-G578.
35. Bolin DR, Cattrell J, Grippa R, et al. Structure activity studies on the vasoactive intestinal peptide pharmacophore. Int J Peptide Protein Res. 1995;46:279-289.
36. Thakur ML, Pallela V, Consigny PM, et al. Tc-99m-TP 1201 for imaging thromboembolism [abstract]. Radiology. 1997;205:P267.
37. Breeman WAP, Hofland LJ, Bakker WH, et al. Effect of dose and specific activity on tissue distribution of In-111 pentreotide in rats. Eur J Nucl Med. 1993;20:1089-1094.
38. Bomanji J, Ur E, Mather S, et al. Scintigraphic comparison of I-123 with an I-123-labeled somatostatin analog (Tyr-3 octreotide) in metastatic carcinoid tumor. J Nucl Med. 1992;33:1121-1124.
39. Lang I, Jaguda E, Wu CH, et al. Factors influencing the in vivo pharmacokinetics of peptides and antibody fragments: the pharmacokinetics of two PET-labeled low molecular weight proteins. Q J Nucl Med. 1997;41:53-61.
40. Kobayashi H, Yoo TM, Kim S, et al. Lysine effectively blocks renal uptake of I-125 or Tc-99m labeled anti-tacdsFV. Cancer Res. 1996;56:3788-3795.